Company: BGLC
Filing Date: 2025-08-18
Form Type: 10-Q
Source: 0001477932-25-006023
Chunk: 35

Company: BioNexus Gene Lab Corp
Filing Date: 2025-08-18
Form: 10-Q
Item: Part I, Item 1
Chunk 35
---
,934)  (558,829)Fair value loss on investments in equity securities   -   (56,136)  -   (56,136)OPERATING EXPENSES   (104,363)  (281,134)  (374,160)  (759,657)                  (LOSS)/PROFIT FROM OPERATIONS   (63,856)  697,184   (374,160)  259,168                   FINANCE COSTS   (2,646)  (1,746)  (88)  (4,480)                  (LOSS)/PROFIT BEFORE TAX   (66,502)  695,438   (374,248)  254,688                   Tax expense   -   (55,584)  -   (55,584)                  NET (LOSS)/PROFIT ATTRIBUTABLE TO COMMON SHAREHOLDERS   $(66,502) $639,854  $(374,248) $199,104 

 26Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE SIX MONTHS ENDED JUNE 30, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Six month period ended June 2025              REVENUE $6,534  $4,390,794  $-  $4,397,328                  COST OF REVENUE  (4,131)  (3,681,682)  -   (3,685,813)                 GROSS PROFIT  2,403   709,112   -   711,515                  OTHER INCOME                Dividend income   -   17,560   -   17,560 Interest income  45,094   8,242   -   53,336 Fair value gain on investments in equity securities  -